Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jeffrey M. Dayno"'
Autor:
Gerard J. Meskill, Craig W. Davis, Donna Zarycranski, Markiyan Doliba, Jean-Charles Schwartz, Jeffrey M. Dayno
Publikováno v:
CNS Drugs
Background Pitolisant, a selective histamine 3 receptor antagonist/inverse agonist, is indicated for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The efficacy and safety of pitolisant have been demonstrated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af53da85d1b0a62b8568257f9be471ee
https://doi.org/10.1007/s40263-021-00886-x
https://doi.org/10.1007/s40263-021-00886-x
Autor:
Nathaniel F. Watson, Jeffrey M Dayno, Ben Vaughn, Donna Zarycranski, Craig W. Davis, Yves Dauvilliers, Jean-Charles Schwartz
Publikováno v:
CNS Drugs
Background Pitolisant is approved in the USA and Europe for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. Objective Analyses evaluated the time to onset of clinical response during treatment with pitolisant. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe886b2ef564a766764b0b35d1d14ca
http://europepmc.org/articles/PMC8642365
http://europepmc.org/articles/PMC8642365
Autor:
Markiyan Doliba, Donna Zarycranski, Jean-Charles Schwartz, Jeffrey M Dayno, Gerard J Meskill, Craig W. Davis
Publikováno v:
Sleep. 44:A198-A199
Introduction When evaluating results of randomized, placebo-controlled trials, the clinical impact of a treatment can be assessed using number needed to treat (NNT; number of patients that need to be treated to achieve a specific outcome for one pers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28147c38a01925610efb3c28b0df9f54
https://doi.org/10.1093/sleep/zsab072.503
https://doi.org/10.1093/sleep/zsab072.503
Publikováno v:
Journal of Opioid Management. 13:111-124
Objective: To characterize the pharmacokinetics (PK) and in vitro alcohol dissolution characteristics of extended-release (ER), injection-molded (IM) morphine tablets with abuse-deterrent (AD) features (morphine-ADER-IMT). Design: In vivo, in vitro,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e0c4bf6fa76aaa6382ce6d4c325ccf
https://doi.org/10.5055/jom.2017.0375
https://doi.org/10.5055/jom.2017.0375
Publikováno v:
The American Journal of Drug and Alcohol Abuse. 43:291-298
Background: US FDA guidance recommends measuring the degree of effort needed to manipulate abuse-deterrent (AD) opioids. The ALERRT® instrument (PinneyAssociates; Bethesda, MD) uses visual analog scales to assess the labor, effort, and resources nec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0d933af217894ae5930102a0a8325e5
https://doi.org/10.1080/00952990.2016.1278006
https://doi.org/10.1080/00952990.2016.1278006
Publikováno v:
Sleep. 43:A291-A292
Introduction This analysis evaluated the efficacy of pitolisant over time in three 7- to 8-week, randomized, placebo-controlled studies of adults with narcolepsy. Methods Patients in all 3 studies (HARMONY-1, HARMONY-1bis, HARMONY-CTP) experienced ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d7b9b257c5461b8c3ac7fc4aae4af3
https://doi.org/10.1093/sleep/zsaa056.764
https://doi.org/10.1093/sleep/zsaa056.764
Autor:
Catherine Scart-Grès, Jean-Charles Schwartz, Beatrice Setnik, Michael McDonnell, Philippe Robert, Jeffrey M Dayno, Catherine Mills
Publikováno v:
Sleep
Objectives To evaluate the human abuse potential of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d41255da3cc89d999e760cdf32d7549
http://europepmc.org/articles/PMC7157189
http://europepmc.org/articles/PMC7157189
Autor:
Gwendolyn Niebler, Jeffrey M. Dayno
Publikováno v:
Postgraduate Medicine. 128:12-17
Opioids are frequently used for treatment of moderate to severe short-term pain, but concerns exist about this treatment approach. Ketorolac tromethamine nasal spray, a nonsteroidal anti-inflammatory, is indicated for the short-term management of mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d466e17a98381dcd9d94b26098461619
https://doi.org/10.1080/00325481.2016.1126185
https://doi.org/10.1080/00325481.2016.1126185
Publikováno v:
Sleep. 43:A291-A291
Introduction Pitolisant Expanded Access Clinical Evaluation (PEACE) provided adult patients with narcolepsy access to treatment with pitolisant while it was an investigational medication in the United States. Methods Pitolisant was titrated to 35.6 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e97c79a3358782195b68f0f1083087a
https://doi.org/10.1093/sleep/zsaa056.762
https://doi.org/10.1093/sleep/zsaa056.762
Publikováno v:
Current medical research and opinion. 34(5)
The development and use of abuse-deterrent (AD) opioids is part of a multifaceted strategy to reduce misuse, abuse, and diversion, while maintaining access for patients with severe pain who may benefit from their analgesic efficacy. Morphine AD, exte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb6c955bc2c711be6fc3f1444792a7b2
https://pubmed.ncbi.nlm.nih.gov/29368961
https://pubmed.ncbi.nlm.nih.gov/29368961